Buy & Sell Banco Bilbao Vizcaya Argentaria SA (BBVA) – Banco Bilbao Vizcaya Argentaria SA Price Today
Aura AI Summary
Key Stats
- $130.28BMarket Cap
- FinancialsSector
- -12.66%3M Drawdown
- -Enterprise Value
- 4.82%Dividend Yield
- 74 daysTypical Hold Time
Banco Bilbao Vizcaya Argentaria SA (BBVA) is currently valued at a market capitalization of $130.28B. Over the past 52 weeks, Banco Bilbao Vizcaya Argentaria SA has traded between a low of $14.73 and a high of $26.11, highlighting its annual price range. Over the past three months, Banco Bilbao Vizcaya Argentaria SA has recorded a drawdown of -12.66%, reflecting recent price volatility. Banco Bilbao Vizcaya Argentaria SA offers a dividend yield of 4.82%, with the most recent dividend of $0.71 paid on 09 Apr 26. On average, investors hold Banco Bilbao Vizcaya Argentaria SA for approximately 74 days, indicating typical investor behavior on the platform.
About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Most Recent News
Bempedoic acid shows promise in lowering LDL-C in children and statin-intolerant adults, per Esperion data.
Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analy...

Rhythm Pharmaceuticals to present at major healthcare conferences in June 2026
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs Global Healthcare Conference on June 8, 2026. These events will be webcast and acce...

Virax Biolabs reports positive early data for ViraxImmune™, a test for Long COVID and related syndromes.
Virax Biolabs announced encouraging early pilot data for ViraxImmune™, a blood test in development to detect Long COVID, ME/CFS, and related post-acute infection syndromes. The test showed 88% specificity and 92% positive predictive value in distingu...
